Dietary ginger may work against cancer growth

October 28, 2003

MINNEAPOLIS / ST. PAUL--The substance that gives ginger its flavor appears to inhibit the growth of human colorectal cancer cells, according to research at the University of Minnesota's Hormel Institute in Austin, Minn. Working with mice that lack an immune system, research associate professor Ann Bode and her colleagues found slower rates of cancer growth in mice given thrice-weekly feedings of [6]-gingerol--the main active component of ginger. Bode and co-author Zigang Dong, director of the institute, will discuss the work at a press conference from 9:30 to 10:30 a.m. MST Tuesday, Oct. 28, during a meeting of the American Association for Cancer Research in the J.W. Marriott Desert Resort and Spa in Phoenix. They will also present the work at a poster session from 1 to 2:30 p.m. and from 6 to 7:30 p.m. MST in the Marriott.

"Plants of the ginger family have been credited with therapeutic and preventive powers and have been reported to have anti-cancer activity," said Bode. "The substance called [6]-gingerol is the main active compound in ginger root and the one that gives ginger its distinctive flavor."

The researchers tested [6]-gingerol's powers by feeding a half milligram to 20 mice three times a week before and after injecting human colorectal tumor cells into their flanks. Control mice were treated the same, except their food contained no [6]-gingerol. Tumors were allowed to grow until they reached a size of one cubic centimeter (0.06 cubic inch), after which the mice were euthanized. The mice, known as athymic nude mice, are often used in such studies because they provide a living-body environment in which tumors can grow without interference from an immune system.

The first tumors appeared 15 days after the cells were injected. At that time, 13 tumors of measurable size had appeared among the control mice, four among the [6]-gingerol-treated mice. Mice consuming [6]-gingerol lagged in both the number of animals with measurable tumors and the average size of tumors within the group. For example, all the mice in the control group had measurable tumors by the 28th day following injection of the cells. But it wasn't until the 38th day that the [6]-gingerol group reached that milestone--but even then, one mouse still had no measurable tumors. As of the 49th day following injection, all control mice had been euthanized due to tumor sizes of one cubic centimeter. In contrast, 12 of the 20 [6]-gingerol mice were still alive on that day, and their average tumor size was about 0.5 cubic centimeter, or half the maximum allowable size.

"These results strongly suggest that ginger compounds may be effective chemopreventive and/or chemotherapeutic agents for colorectal carcinomas," said Bode. Because mice were not allowed to live with tumors bigger than one cubic centimeter, "it's difficult to know if the ginger-treated mice would have lived longer if left to die of their tumors, but it looks that way," she said.

Preliminary results also suggested that tumors in the control mice had spread, or metastasized, more than tumors in the [6]-gingerol mice, but whether a significant difference actually exists remains to be verified, Bode said.

In these experiments, mice were fed ginger before and after tumor cells were administered. In their next round of experiments, the researchers plan to feed ginger to mice only after they have grown tumors to a certain size.

"The new experiments should be more clinically relevant," said Bode. "They will get at the question of whether a patient could eat ginger to slow the metast of a nonoperable tumor."

The University of Minnesota has applied for a patent on the use of [6]-gingerol as an anti-cancer agent, and the technology has been licensed to Pediatric Pharmaceuticals (Iselin, N.J.) The work was supported by the Hormel Foundation and Pediatric Pharmaceuticals.
-end-
Contacts:
Ann Bode, 651-210-4045 (cell); 480-293-5000 (J.W. Marriott Desert Resort and Spa, Phoenix)
Deane Morrison, University News Service, 612-624-2346

University of Minnesota

Related Tumor Cells Articles from Brightsurf:

A more sensitive way to detect circulating tumor cells
Breast cancer is the most frequently diagnosed cancer in women, and metastasis from the breast to other areas of the body is the leading cause of death in these patients.

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

How to prevent the spread of tumor cells via the lymph vessels
Scientists from the German Cancer Research Center and the Mannheim Medical Faculty of the University of Heidelberg identified a new way to block the dangerous spread of tumor cells via lymphatic vessels.

The CNIO reprograms CRISPR system in mice to eliminate tumor cells without affecting healthy cells
CNIO researchers destroyed Ewing's sarcoma and chronic myeloid leukaemia tumor cells by using CRISPR to cut out the fusion genes that cause them.

Feeding off fusion or the immortalization of tumor cells
Despite all recent progress, cancer remains one of the deadliest human diseases.

How do tumor cells divide in the crowd?
Scientists led by Dr. Elisabeth Fischer-Friedrich, group leader at the Excellence Cluster Physics of Life (PoL) and the Biotechnology Center TU Dresden (BIOTEC) studied how cancer cells are able to divide in a crowded tumor tissue and connected it to the hallmark of cancer progression and metastasis, the epithelial-mesenchymal transition (EMT).

How tumor cells evade the immune defense
Scientists are increasingly trying to use the body's own immune system to fight cancer.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

New pathway to attack tumor cells identified
A study led by the Institut de Neurociències (INc-UAB) describes a new strategy to tackle cancer, based on inducing a potent stress in tumor causing cell destruction by autophagy.

Nutrient deficiency in tumor cells attracts cells that suppress the immune system
A study led by IDIBELL researchers and published this week in the American journal PNAS shows that, by depriving tumor cells of glucose, they release a large number of signaling molecules.

Read More: Tumor Cells News and Tumor Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.